JP2018512124A5 - - Google Patents

Download PDF

Info

Publication number
JP2018512124A5
JP2018512124A5 JP2017546179A JP2017546179A JP2018512124A5 JP 2018512124 A5 JP2018512124 A5 JP 2018512124A5 JP 2017546179 A JP2017546179 A JP 2017546179A JP 2017546179 A JP2017546179 A JP 2017546179A JP 2018512124 A5 JP2018512124 A5 JP 2018512124A5
Authority
JP
Japan
Prior art keywords
binding protein
independently
linker
amino acid
isolated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017546179A
Other languages
English (en)
Japanese (ja)
Other versions
JP6745275B2 (ja
JP2018512124A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/020780 external-priority patent/WO2016141245A1/en
Publication of JP2018512124A publication Critical patent/JP2018512124A/ja
Publication of JP2018512124A5 publication Critical patent/JP2018512124A5/ja
Application granted granted Critical
Publication of JP6745275B2 publication Critical patent/JP6745275B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017546179A 2015-03-04 2016-03-03 トランスフォーミング増殖因子β1に高親和性、アビディティおよび特異性で結合する修飾IgG抗体 Active JP6745275B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562128149P 2015-03-04 2015-03-04
US62/128,149 2015-03-04
PCT/US2016/020780 WO2016141245A1 (en) 2015-03-04 2016-03-03 Modified-igg antibodies that bind transforming growth factor-beta1 with high affinity, avidity and specificity

Publications (3)

Publication Number Publication Date
JP2018512124A JP2018512124A (ja) 2018-05-17
JP2018512124A5 true JP2018512124A5 (enExample) 2019-03-28
JP6745275B2 JP6745275B2 (ja) 2020-08-26

Family

ID=55524479

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017546179A Active JP6745275B2 (ja) 2015-03-04 2016-03-03 トランスフォーミング増殖因子β1に高親和性、アビディティおよび特異性で結合する修飾IgG抗体

Country Status (22)

Country Link
US (4) US11325970B2 (enExample)
EP (3) EP3265487B1 (enExample)
JP (1) JP6745275B2 (enExample)
KR (3) KR20240076851A (enExample)
CN (1) CN107787329B (enExample)
AR (1) AR103840A1 (enExample)
AU (1) AU2016226098B2 (enExample)
DK (1) DK3265487T3 (enExample)
ES (2) ES2994790T3 (enExample)
HR (1) HRP20221142T1 (enExample)
HU (1) HUE059644T2 (enExample)
IL (1) IL254239B2 (enExample)
LT (1) LT3265487T (enExample)
MX (1) MX382703B (enExample)
PL (1) PL3265487T3 (enExample)
PT (1) PT3265487T (enExample)
RS (1) RS63589B1 (enExample)
RU (1) RU2728858C2 (enExample)
SG (2) SG10201908019UA (enExample)
SI (1) SI3265487T1 (enExample)
TW (1) TWI733661B (enExample)
WO (1) WO2016141245A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI726870B (zh) 2015-03-04 2021-05-11 美商健臻公司 具有高親和性、結合性及專一性之結合轉形生長因子-β1的scFv-Fc二聚體
TWI733661B (zh) 2015-03-04 2021-07-21 美商健臻公司 以高親合性、結合性及特異性結合轉化生長因子-β1的經修飾IgG抗體
PL3365368T3 (pl) 2016-03-11 2023-08-21 Scholar Rock, Inc. Immunoglobuliny wiążące tgfbeta1 i ich zastosowanie
US11326182B2 (en) 2016-04-29 2022-05-10 Voyager Therapeutics, Inc. Compositions for the treatment of disease
WO2017189964A2 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
TWI788321B (zh) 2017-01-20 2023-01-01 美商健臻公司 骨靶向抗體
TWI787230B (zh) * 2017-01-20 2022-12-21 法商賽諾菲公司 抗TGF-β抗體及其用途
SG11202100087WA (en) * 2018-05-10 2021-02-25 Mirabiologics Inc Artificial protein containing an antibody antigen-binding region, fused with bioactive peptides
US12252531B2 (en) 2018-07-11 2025-03-18 Scholar Rock, Inc. Methods of screening for high-affinity, isoform-selective TGFβ1 inhibitors
US20250270325A1 (en) * 2020-03-31 2025-08-28 Medimmune, Llc Stabilized igg4 antibodies and uses thereof
US20220119513A1 (en) * 2020-06-08 2022-04-21 Zoetis Services Llc Anti-tgfb antibodies and therapeutic uses thereof
JP7798806B2 (ja) * 2020-06-12 2026-01-14 ブリストル-マイヤーズ・スクイブ・ティージーエフ・ベータ・インコーポレイテッド 形質転換成長因子β(TGFβ)結合剤及びその使用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020099179A1 (en) 1989-12-21 2002-07-25 Linda K. Jolliffe Cdr-grafted antibodies
US5616561A (en) 1995-03-31 1997-04-01 Regents Of The University Of California TGF-β antagonists as mitigators of radiation-induced tissue damage
US6492497B1 (en) * 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
EP1486560A3 (en) 1999-04-30 2005-02-09 Cambridge Antibody Technology LTD Specific antibodies and antibody fragments for TGFBETA1
US20060286105A1 (en) 2003-04-30 2006-12-21 Steven Ledbetter Tgf-beta antagonists combined with renin-angiotensin-aldosteron-system antagonists for treating renal insufficiency
CA2561686C (en) * 2004-03-31 2014-12-02 Genentech, Inc. Humanized anti-tgf-beta antibodies
EP1796715A2 (en) 2004-09-22 2007-06-20 Genzyme Corporation USE OF TGF-ß ANTAGONISTS TO LIMIT NEPHROTOXICITY OF IMMUNOSUPPRESSIVE AGENTS
US9284375B2 (en) 2005-04-15 2016-03-15 Macrogenics, Inc. Covalent diabodies and uses thereof
CA2607448C (en) 2005-04-22 2014-11-18 Eli Lilly And Company Tgf beta 1 specific antibodies
ES2379194T3 (es) 2005-12-23 2012-04-23 Eli Lilly And Company Anticuerpos de unión a TGF-beta
CN103073639A (zh) 2006-03-17 2013-05-01 比奥根艾迪克Ma公司 稳定的多肽组合物
TW200808347A (en) 2006-03-23 2008-02-16 Kirin Brewery Agonistic antibody directed against human thrombopoietin receptor
EP2918288B1 (en) 2006-10-03 2017-08-16 Genzyme Corporation Use of TGF beta antagonists to treat infants at risk of developing bronchopulmonary dysplasia
EA019512B1 (ru) 2008-07-02 2014-04-30 Эмерджент Продакт Дивелопмент Сиэтл, Ллс Il-6-опосредованная иммунотерапия
US20120294868A1 (en) * 2009-04-24 2012-11-22 Edwards James R Anti-tgf-beta induction of bone cell function and bone growth
EP2655624B1 (en) 2010-12-23 2017-11-29 Biogen MA Inc. Linker peptides and polypeptides comprising same
TWI838039B (zh) * 2011-03-28 2024-04-01 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
PH12013502489B1 (en) * 2011-06-03 2019-04-24 Xoma Technology Ltd Antibodies specific for tgf-beta
CA2878587A1 (en) 2012-07-23 2014-01-30 Zymeworks Inc. Immunoglobulin constructs comprising selective pairing of the light and heavy chains
PL2971048T4 (pl) 2013-03-11 2019-05-31 Genzyme Corp Zmodyfikowane przeciwciała anty-TGF-beta i fragmenty wiążące antygen
SI3312195T1 (sl) * 2013-03-20 2020-02-28 Genzyme Corporation Postopki zdravljenja osteogeneze imperfecta
TWI733661B (zh) 2015-03-04 2021-07-21 美商健臻公司 以高親合性、結合性及特異性結合轉化生長因子-β1的經修飾IgG抗體
TWI726870B (zh) 2015-03-04 2021-05-11 美商健臻公司 具有高親和性、結合性及專一性之結合轉形生長因子-β1的scFv-Fc二聚體

Similar Documents

Publication Publication Date Title
RU2017134043A (ru) Модифицированные антитела igg, которые связываются с трансформирующим фактором роста бета-1 с высокой аффинностью, авидностью и специфичностью
US20230203173A1 (en) Tumor necrosis factor (tnf) superfamily receptor igm antibodies and uses thereof
JP2022079549A5 (enExample)
JP2020500538A5 (enExample)
EA201991099A1 (ru) Антитела против cd73 и их применение
JP2021516057A5 (enExample)
JP2020536109A5 (enExample)
JP2020515508A5 (enExample)
JP2016525551A5 (enExample)
FI3922645T3 (fi) Pro-/latentin myostatiinin vasta-aineita ja niiden käyttötapoja
MX2012008999A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340015B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX2012009000A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340016B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
HRP20161656T4 (hr) Sredstva za vezanje na cd33
RU2016101711A (ru) Высокостабильный т-клеточный рецептор и способ его получения и применения
JP2018502572A5 (enExample)
JP2019501883A5 (enExample)
JP2014518615A5 (enExample)
JP2019506841A5 (enExample)
JP2017529067A5 (enExample)
CN107108737B (zh) c-met特异性人抗体及其制备方法
NZ602892A (en) Antibodies that bind human cd27 and uses thereof
JP2025508118A (ja) 新規免疫調節剤の開発および使用
JP2017113019A5 (enExample)